Recursion announces first patient dosed in Phase 1/2
Dec 3, 2024 · Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma …
Recursion Begins First-in-Human Trial for AI-Discovered Protein ...
Dec 3, 2024 · In October 2024, Recursion Pharmaceuticals received FDA clearance to initiate clinical trials for REC-1245, an investigational RBM39 degrader targeting biomarker-enriched …
Recursion’s REC-1245 IND Cleared by FDA for Phase 1/2 Trial
Nov 6, 2024 · Recursion, a clinical-stage TechBio company leveraging AI for drug discovery, has announced that the FDA has cleared an investigational new drug (IND) application for its …
Recursion Announces First Patient Dosed in Phase 1/2 Clinical …
Recursion recently announced the first patient has been dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and …
Recursion announces first patient dosed in Phase 1/2 clinical …
About REC-1245 REC-1245 is a novel molecular glue that leads to the degradation of RBM39 via E3 ligase adaptor DCAF15, which disrupts RNA splicing to downregulate cell cycle …
SEED Therapeutics Highlights Breakthrough Advances in Targeted …
May 5, 2025 · SEED’s strategic collaborations with Eli Lilly and Company and Eisai Co., Ltd. support its mission to develop transformational therapies, with its lead RBM39 degrader …
AI-Driven Cancer Therapy: Recursion Doses First Patient in REC …
Dec 6, 2024 · Recursion has begun Phase 1/2 trials for REC-1245, a groundbreaking therapy targeting RBM39 in biomarker-enriched solid tumors and lymphoma. Developed using AI, REC …
Recursion Announces FDA Clearance of Investigational New
Oct 2, 2024 · The Phase 1/2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential monotherapy efficacy of REC-1245, and is expected to …
FDA Clears Recursion’s IND for REC-1245, a Potential First-In-Class ...
Oct 2, 2024 · Recursion announced that the FDA cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment …
Recursion Begins Phase I/II Trial of REC-1245 in Solid Tumors ...
REC-1245 is a molecular glue that degrades the protein RBM39, which leads to the downregulation of cell cycle checkpoints and DNA damage response networks, including CDK12.
- Some results have been removed